Background Empiric steroid therapy is the first-line therapy for pediatric nephrotic syndrome, but treatment response is variable. There are few predictors of steroid-responsiveness, although evidence for genetic factors does exist. Single nucleotide polymorphisms (SNPs) have been recently identified in the promoter region of glucocorticoid-induced transcript 1 gene (GLCCI1) which affect steroid-responsiveness in asthmatic patients. Independently, GLCCI1 was identified as a podocyte protein, the loss of which disrupts the function of the glomerular filtration barrier. We therefore examined whether SNPs associated with the steroidresponsive expression of GLCCI1 might predict steroidresponsiveness in nephrotic syndrome.
Introduction
Idiopathic nephrotic syndrome is the most common kidney disease in children. In these cases, empiric treatment with high-dose steroids is the current standard of care [1] . While the relatively high response rates in this population warrant the approach, the treatment does carry the risk of significant adverse effects. Identifying predictors to differentiate steroid-sensitive nephrotic syndrome (SSNS) from steroidresistant nephrotic syndrome (SRNS) has the potential to limit exposure to steroids in patients unlikely to benefit from these medications. Age at disease onset is the only wellestablished clinical parameter that influences response to treatment, and there are no established laboratory tests that can differentiate SSNS and SRNS. Histological factors found on renal biopsy, such as the underlying primary glomerular pathology, have clear implications on the likelihood of a clinical response to steroids, but require an invasive procedure usually deferred in the pediatric patient. Over the last decade, there have been substantial efforts to identify factors that influence responsiveness to treatment, including serum cytokine levels [2] and urinary biomarkers [3] , but with little success. There has, however, been substantial progress in identifying genetic mutations which lead to hereditary forms of nephrotic syndrome [4] . Many of these Mendelian forms of disease are generally unresponsive to conventional treatment. This provides clinical utility to testing for these mutations [5] , allowing affected patients to avoid unnecessary exposure to steroids. Efforts have also been made to identify common genetic polymorphisms that confer the risk of developing disease or steroid-responsiveness. Variants and haplotypes of various genes have been reported to influence disease risk, including apolipoprotein L1 (APOL1) [6, 7] and glypican-5 (GPC5) [8] , among others. However, reported associations have been inconsistent in many cases, as exemplified by the results of a recent meta-analysis of the ACE I/D polymorphism [9] .
In a recently reported genome-wide association study examining the response of asthmatic patients to inhaled glucocorticoids, two single nucleotide polymorphisms (SNPs) in complete linkage disequilibrium in the promoter region of GLCCI1 were found to associate with a poorer response to steroid treatment [10] . The variants were associated with decreased expression levels of GLCCI1 in lymphoblastoid B cells, both at baseline and in response to dexamethasone treatment. Independently, Tryggvason and colleagues reported that GLCCI1 is specifically expressed in podocytes and mesangial cells in the kidney and that the knockdown of GLCCI1 in zebrafish embryos leads to the development of proteinuria, abnormal glomerular capillary loops, and podocyte foot process defects [11] . Based on these results, we hypothesized that the SNPs that alter GLCCI1 expression and steroid-responsiveness in asthmatic patients might also impact the risk of developing nephrotic syndrome or of responding to glucocorticoid therapy for nephrotic syndrome. In genotyping 211 pediatric patients with nephrotic syndrome and 102 controls, there were no statistically significant associations between the SNPs associated with a poorer response to glucocorticoid therapy in asthmatics and either the development of nephrotic syndrome or with initial response to steroid therapy.
Methods

Patients
A total of 226 pediatric patients diagnosed with nephrotic syndrome by the Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea were enrolled in the study between 1983 and 2011. Diagnostic criteria, initial treatment, and response criteria were as previously described [12] . Briefly, nephrotic syndrome was defined as proteinuria >40 mg/h/m 2 with associated hypoalbuminemia of <2.5 g/dL. Initial treatment was with oral prednisolone 60 mg/m 2 /day or an equivalent dose of deflazacort for 4 weeks, followed by a dose of 40 mg/m 2 every other day for 4 additional weeks. The initial steroid response was defined as the absence of proteinuria on dipstick test or <4 mg/ m 2 /day for at least 3 consecutive days. Of the 226 patients, 15 were excluded from the analysis due to incomplete clinical records, the presence of secondary forms of disease (including 6 patients with familial forms involving mutations in the LMX1B, ACTN4, INF2, and MYH9 genes), or poor quality DNA for genotyping. All patients were screened to rule out mutations in NPHS2 and WT1 (exons 8 and 9). One hundred and two controls were enrolled at the same clinical center.
Informed consent for genetic analysis was obtained from all patients and/or their parents. The Institutional Review Board of Seoul National University Hospital, Seoul, Korea approved the protocols used in this study.
Genotyping
Genomic DNA was obtained from a sample of peripheral blood using a QIA Amp DNA Blood Mini kit (Qiagen, Valencia, CA). The genotypes of SNPs rs37972 and rs37973 were determined using validated TaqMan SNP Genotyping assays from Applied Biosciences (Foster City, CA) and the TaqMan Genotyping Master Mix. Genotyping reactions were run in 384 well plates on an ABI Real Time PCR machine as per the manufacturer's recommendation, with automated allele calling.
Statistical analysis
Analysis for an association of genotypes with different groups in an additive model was performed using the Cochran-Armitage trend test in XLSTAT (Addinsoft, Paris, France) and Excel (Microsoft, Redwood, WA). Odds ratios, p values, and 95 % confidence intervals of allele and genotype frequencies between groups were calculated using Fisher's exact test on Prism 5 software (GraphPad, San Diego, CA).
Power calculations assuming an additive model, an odds ratio of 2.4 between persons homozygous for the major allele and persons homozygous for the minor allele, and a minor allele frequency of 0.4 gave a power of 62 % at an alpha of 0.05 for the evaluation of cases and controls, and a 50 % power for comparison of steroid-responsive and nonresponsive cases.
Results
The average patient age at the time of diagnosis was 6.0± 3.8 years (range 6 months to 18 years); 71 % were male. Of the 211 patients, 117 (55 %) were deemed initial steroid responders, and 120 patients underwent renal biopsy. All steroid-resistant patients underwent biopsy unless there was a contra-indication; frequent relapses and steroid dependence were relative indications for a renal biopsy, and some of these patients underwent biopsy. The pathologic diagnosis was minimal change disease (MCD) in 42 patients (35 %), focal and segmental glomerulosclerosis (FSGS) in 76 patients (63 %), and C1q nephropathy in two patients.
Genotype and allele frequencies for the SNPs rs37972 and rs37973 are shown in Table 1 ; no significant deviation from Hardy-Weinberg equilibrium was observed. Minor allele frequencies were similar to those reported by the HapMap consortium for Han Chinese in Beijing (43 % for both SNPs) and Japanese in Tokyo (38 and 41 % for rs37972 and rs37973, respectively) [13] .
Prespecified comparisons were performed between cases and controls and between steroid-responsive and nonresponsive patients. In an additive model, no statistically significant differences were noted between these groups (p values 0.567 for both SNPs comparing cases and controls; p values of 0.414 and 0.344 for rs37972 and 37973, respectively, comparing steroid responders and non-responders; Cochran-Armitage trend test). Analysis of the data using various models, as well as by comparison of allele frequencies, did not demonstrate any statistically significant associations (Electronic Supplementary Material Table 1 ). Posthoc analysis of subgroups with biopsy-proven MCD or FSGS did suggest a relatively lower proportion of patients homozygous for the major alleles at both loci in the steroid non-responsive group compared to those who were steroidresponsive. However, the differences did not reach statistical significance, and the small number of individuals in these subgroups, as well as potential selection biases in pursuing biopsy warrant caution in interpreting these results.
Discussion
In this study, we determined the allele and genotype frequencies of GLCCI1 SNPs rs37972 and rs37973 in a cohort of pediatric patients with idiopathic nephrotic syndrome and control samples. Interest in these particular SNPs was based on two recent reports: (1) these SNPs confer a higher risk of poor response to inhaled steroids in asthmatic patients and decrease GLCCI1 expression in B cell lines [10] , and (2) GLCCI1 is highly expressed in the renal glomerulus and knockdown of the transcript impairs the glomerular filtration barrier in developing zebrafish [11] . We found no statistically significant association with the minor alleles, linked to a poorer response of asthmatic patients to inhaled glucocorticoids, and nephrotic syndrome or initial steroidresponsiveness. A post-hoc subgroup analysis does suggest that further examination of these SNPs in patients with biopsy-confirmed MCD or FSGS is warranted.
Our understanding of the function of GLCCI1 remains limited. It was initially identified as a transcript rapidly upregulated in response to glucocorticoid treatment in cells derived from a thymoma [14] and is found predominantly expressed in lymphoid tissue and cell lines, lung, and brain [10, 11] . In the kidney, it appears to be expressed specifically in mesangial cells and podocytes [11] . Morpholino-mediated knockdown of the gene in zebrafish embryos impairs the proper formation of the glomerulus and of podocyte foot processes. However, at a cellular level, the function of GLCCI1 remains unknown, and it has no well-defined protein domains other than a short coiled-coil sequence.
Our study has several limitations that should be noted. Sample size, coupled with the usually low effect size of relatively common variants, is frequently a limitation of genetic studies examining the potential role of genetic variants on disease prevalence. While we limited our analysis of GLCCI1 to two SNPs with an established association with gene expression and a relatively robust odds ratio for glucocorticoid response in asthmatics [10] , our cohort was underpowered to be able to reliably detect an effect size similar to that reported for rs37973 in asthmatics. The use of a dichotomous outcome in our study, as opposed to the continuous variable of change in forced expiratory volume in 1 second (FEV1) used by Tantisira et al [10] , contributed to this. Nonetheless, our results do suggest that these SNPs are unlikely to provide clinically actionable information for initial treatment of pediatric nephrotic syndrome. Secondly, our study was limited to patients of Korean nationality. While this strategy helps to limit the possibility of underlying population stratification between groups, we cannot rule out the possibility that the SNPs examined might be associated with a significant effect on steroid-responsiveness in the background of a different ancestry. Finally, a review of dbSNP (www.ncbi.nlm.nih.gov/projects/SNP/) revealed dozens of SNPs surrounding and within GLCCI1, including several missense variants. It is certainly possible that one or more of these variants could influence either gene function or expression specifically in glomerular cells, and thereby alter susceptibility to proteinuric kidney disease or its response to treatment. The development of a larger cohort of patients and controls, or additional results pointing to the potential relevance of a particular variant, will be needed before the evaluation of additional variants is feasible. Similarly, analysis of an adult cohort of biopsy-proved MCD or FSGS will likely be needed to followup the potential correlation of rs37973 and rs37972 and steroidresponsiveness in these subtypes of nephrotic syndrome. GLPCCl1, Glucocorticoid-induced transcript 1 gene; MCD, Minimal change disease; FSGS, focal segmental glomerulosclerosis; H-W Eq, Hardy-Weinberg equilibrium
